Clinical trial of intravitreal activated Protein C (Anact C&reg;) for central retinal vein occusion

Clinical trial of intravitreal activated Protein C (Anact C&reg;) for central retinal vein occusion - Intravitreal APC for CRVO

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008976

Enrollment

Registered

2012-09-25

Start date

2011-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central retinal vein occlusion

Interventions

Intravitreal injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Central retinal vein occlusion One month or less after the onset Visual acuity between 20/2000 and 20/50 Central foveal thickness of 350um or more

Exclusion criteria

Exclusion criteria: Cases with other retinal disorder such as diabetic retinopathy or macular diseases. Cases with other serious eye diseases such as glaucoma. Cases with previous treatments such as steroid therapy, anti-VEGF therapy or laser photocoagulation.

Design outcomes

Primary

Measure	Time frame
Visual acuity, intraocular pressure, slit lamp and fundus examination, and optical coherence tomography before and at 2 days, 2 weeks, 1, 2, 3, 6, 9 and 12 months after injection. Recording any adverse effects.	—

Secondary

Measure	Time frame
Fluorescein angiography for evaluating retinal circulation at 6 and 12 months after injection.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

Clinical trial of intravitreal activated Protein C (Anact C&amp;reg;) for central retinal vein occusion